Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Prog Neuropsychopharmacol Biol Psychiatry ; 39(1): 170-4, 2012 Oct 01.
Article in English | MEDLINE | ID: mdl-22750309

ABSTRACT

OBJECTIVE: Many chronic inpatients with schizophrenia demonstrate enduring psychiatric symptoms and various side effects of antipsychotic drugs. Several biological markers such as prolactin, thyroid hormones and brain-derived neurotrophic factor (BDNF) are reportedly associated with psychiatric symptoms and/or antipsychotic side effects in patients with schizophrenia but to date findings are inconsistent. The objective of the present study was to comprehensively investigate the association of psychiatric and extrapyramidal symptoms with hormones and BDNF in chronic schizophrenia. METHODS: In this study, 93 chronic inpatients with schizophrenia were comprehensively investigated in order to examine the association of psychiatric and extrapyramidal symptoms with prolactin, thyroid hormones (free triiodothyronine (T3), free thyroxine (T4), thyroid stimulating hormone), cortisol and BDNF. Symptoms were assessed via the Positive and Negative Syndrome Scale (PANSS), Mini-Mental State Examination (MMSE), and drug-induced extrapyramidal symptoms scale (DIEPSS). RESULTS: Multiple regression analyses revealed that antipsychotic dose was the only variable that predicted significant variance in PANSS positive subscale scores, that BDNF and free T3 predicted significant variance in MMSE scores, and that prolactin and free T3 predicted significant variance in DIEPSS scores. CONCLUSION: These findings suggest that BDNF, free T3, and prolactin may be associated with cognitive function and/or extrapyramidal symptoms in patients with chronic schizophrenia. Notably, free T3 may be possibly associated with better cognitive function and less extrapyramidal symptoms, although our cross-sectional study could not reveal a causal relationship.


Subject(s)
Cognition , Schizophrenia/physiopathology , Schizophrenic Psychology , Triiodothyronine/physiology , Adult , Aged , Aged, 80 and over , Antipsychotic Agents/adverse effects , Basal Ganglia Diseases/blood , Basal Ganglia Diseases/complications , Basal Ganglia Diseases/diagnosis , Basal Ganglia Diseases/psychology , Brain-Derived Neurotrophic Factor/blood , Chronic Disease , Cognition/drug effects , Cognition/physiology , Female , Humans , Hydrocortisone/blood , Male , Middle Aged , Neuropsychological Tests/statistics & numerical data , Prolactin/blood , Psychiatric Status Rating Scales/statistics & numerical data , Schizophrenia/blood , Schizophrenia/complications , Severity of Illness Index , Thyrotropin/blood , Thyroxine/blood , Triiodothyronine/blood
2.
Neuropeptides ; 41(6): 477-83, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17767955

ABSTRACT

Hepatocyte growth factor (HGF) is induced in neurons during ischemia and is neuroprotective against post-ischemic delayed neuronal death in the hippocampus. HGF might play an important role in the maturation and functioning of these neurons in the hippocampus. Our aim was to determine what effect HGF antisense has on depression and anxiety in rats. HGF antisense was infused at a constant rate into cerebral lateral ventricles and its effect on anxiety in rats was monitored. In forced swimming test, rats that received antisense DNA increased the length of time that they were immobile in the water. In the elevated plus maze test, the black and white box test and conditioned fear test, HGF antisense administration caused all indicators of anxiety to increase. Number of HGF-positive cells in C1 of hippocampus was significantly decreased in the HGF antisense-infused group compared to the vehicle- and scrambled oligonucleotide-treated group. No significant effect on general locomotor activity was seen. These results indicate that inhibition of HGF induces an increase in depression and anxiety-related behaviors suggesting a depressive and anxiogenic-like effect.


Subject(s)
Anxiety/chemically induced , DNA, Antisense/pharmacology , Depression/chemically induced , Hepatocyte Growth Factor/antagonists & inhibitors , Animals , Behavior, Animal/drug effects , DNA, Antisense/administration & dosage , Hepatocyte Growth Factor/genetics , Lateral Ventricles , Male , Rats , Rats, Wistar
3.
Neuropsychobiology ; 55(1): 21-7, 2007.
Article in English | MEDLINE | ID: mdl-17556849

ABSTRACT

BACKGROUND: It is commonly believed that there exists a relationship between the outcome of thyrotropin-releasing hormone (TRH) test, the combined dexamethasone/corticotropin-releasing hormone (DEX/CRH) test and stressful life events (SLEs) in major depressive disorder. OBJECTIVE: SLEs influence the TRH and DEX/CRH tests in major depressive disorder when administered at the time of admission and improvement. METHODS: The TRH and DEX/CRH tests were administered to patients hospitalized for major depressive disorders - on the 4th through the 7th hospital day and at the time of improvement. We measured DeltaMAX TSH, DeltaMAX ACTH, ACTH AUC, DeltaMAX cortisol, cortisol AUC, DeltaMAX ACTH/DeltaMAX TSH and DeltaMAX cortisol/DeltaMAX TSH. RESULTS: SLEs were significantly negatively associated with DeltaMAX ACTH, ACTH AUC and cortisol AUC at the time of admission. However, these relationships lost significance at the time of improvement. The sample (41 patients at the time of admission, 18 patients at the time of improvement) was relatively small, which may have contributed to false-negative results. CONCLUSION: SLEs may be negatively associated with the outcome of the DEX/CRH tests in major depressive disorder. The hypothalamic-pituitary-adrenal axis in the DEX/CRH test was modulated by SLEs.


Subject(s)
Adrenocorticotropic Hormone/metabolism , Depressive Disorder, Major/metabolism , Hydrocortisone/metabolism , Hypothalamo-Hypophyseal System/metabolism , Life Change Events , Pituitary-Adrenal System/metabolism , Adult , Area Under Curve , Corticotropin-Releasing Hormone , Dexamethasone , Female , Humans , Hypothalamo-Hypophyseal System/drug effects , Male , Middle Aged , Pituitary-Adrenal Function Tests/methods , Pituitary-Adrenal System/drug effects , Retrospective Studies , Statistics, Nonparametric
4.
Biol Psychol ; 74(1): 34-8, 2007 Jan.
Article in English | MEDLINE | ID: mdl-16893600

ABSTRACT

It has been suggested that frontal brain asymmetry is associated with differences in basic emotional dimensions, particularly in activation of systems underlying avoidance-withdrawal behavior. We examined regional cerebral oxygenated hemoglobin (O2Hb) levels in human medial prefrontal cortex (MPFC) using near-infrared reflection spectroscopy (NIRS) prior to and during anticipatory anxiety to determine if NIRS could detect any anxiety-related changes. Transient anxiety was induced in 56 normal volunteers by anticipation and a painful shock to the right-hand's median nerve. Pre- and post-anxiety affective statuses were measured using the State-Trait Anxiety Inventory (STAI) and Temperature Character Inventory (TCI). NIRS recorded from the left and right frontal brain regions. Right MPFC O2Hb was significantly increased relative to left MPFC O2Hb during anticipation of the shock. Right-sided O2Hb increases were significantly correlated with the TCI Harm Avoidance subscale. These results support the hypothesis that O2Hb levels in the right frontal region correlate with anxiety or heightened negative affect.


Subject(s)
Anxiety Disorders/physiopathology , Anxiety Disorders/psychology , Electroencephalography , Functional Laterality/physiology , Prefrontal Cortex/physiopathology , Adult , Character , Female , Harm Reduction , Humans , Male , Oximetry , Personality Inventory , Surveys and Questionnaires , Temperature
SELECTION OF CITATIONS
SEARCH DETAIL